LSDIF (Lucy Scientific Discovery) ROE % Adjusted to Book Value: -13.53% (As of Dec. 2023)


What is Lucy Scientific Discovery ROE % Adjusted to Book Value?

Lucy Scientific Discovery LSDIF ROE % Adjusted to Book Value is -13.53% as of Dec. 2023.

Lucy Scientific Discovery's ROE % for the quarter that ended in Dec. 2023 was -753.14%. Lucy Scientific Discovery's PB Ratio for the quarter that ended in Dec. 2023 was 55.66. Lucy Scientific Discovery's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -13.53%.

Lucy Scientific Discovery ROE % Adjusted to Book Value Related Terms

Lucy Scientific Discovery ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery ROE % Adjusted to Book Value Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
0.00 0.00 0.00

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -45.18 -55.24 -13.53

LSDIF vs INQD, ZTS, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's ROE % Adjusted to Book Value falls into.


Lucy Scientific Discovery ROE % Adjusted to Book Value Calculation

Lucy Scientific Discovery's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 4.29
=0.00%

Lucy Scientific Discovery's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-753.14% / 55.66
=-13.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -13.53% mean?
Lucy Scientific Discovery (LSDIF) has a ROE % Adjusted to Book Value of -13.53% as of Dec. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lucy Scientific Discovery and its competitors.
Is Lucy Scientific Discovery's ROE % Adjusted to Book Value too high?
Lucy Scientific Discovery's current ROE % Adjusted to Book Value is -13.53%.
How does Lucy Scientific Discovery's ROE % Adjusted to Book Value compare to INQD and ZTS?
Lucy Scientific Discovery's ROE % Adjusted to Book Value of -13.53% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lucy Scientific Discovery and its competitors. Lucy Scientific Discovery's current ROE % Adjusted to Book Value is -13.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current ROE % Adjusted to Book Value of -13.53%. The current ROE % Adjusted to Book Value is -13.53%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current ROE % Adjusted to Book Value is -13.53% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.